Add that to a GLP-1 prescription and you have a recipe for success
This is a research compound with no FDA-approved use
Probiotics and non-alcoholic fatty liver disease: unveiling the mechanisms of Lactobacillus plantarum and Bifidobacterium bifidum in modulating lipid metabolism, inflammation, and intestinal barrier integrity
As a result, individuals may experience quicker improvements in their health, such as reduced inflammation, clearer skin, and higher energy levels, making IV glutathione therapy an attractive option for many
Liraglutide (LIRA) and semaglutide (SEMA) gained approval by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for weight reduction in obese individuals or people who are overweight with BMI 27 kg/m 2 and also experience at least one weight-associated comorbid situation (such as hypertension, dyslipidemia, prediabetes and OSA) combined to lifestyle modifications [71]
The patient and clinician should set mutual goals in these areas